PTC Therapeutics Enhances Workforce with Restricted Stock Units for New Hire Inducement Package

PTC Therapeutics Strengthens Workforce with New Hire Inducement Package

PTC Therapeutics, Inc. has taken a significant step in enhancing its workforce by approving the issuance of 300 restricted stock units (RSUs) to a newly hired non-executive employee, effective January 2, 2026. This move aligns with the company's strategy to attract and retain top talent within the biopharmaceutical sector. The RSUs, which grant the right to receive one share of common stock upon vesting, are part of the employment compensation package and have been approved by the company’s Compensation Committee. By offering this inducement grant, PTC Therapeutics not only complies with the Nasdaq Listing Rule 5635(c)(4) but also demonstrates its commitment to fostering an engaging workplace environment that prioritizes employee satisfaction and retention.

The vesting period for these RSUs spans four years, with 25% of the units becoming available to the employee on each annual anniversary of the hire date, contingent upon the individual’s continued service with the company. This structured vesting schedule is designed to encourage long-term employment and align the interests of the new hire with those of the company, thus promoting a culture of commitment and collaboration. By investing in its employees through equity-based compensation, PTC Therapeutics aims to motivate its workforce, drive productivity, and ultimately enhance the company’s ability to deliver innovative therapies for patients with rare disorders.

As a leading global biopharmaceutical enterprise, PTC Therapeutics is dedicated to discovering, developing, and commercializing groundbreaking medicines for individuals facing rare diseases. The company’s diverse pipeline of transformative therapies reflects its mission to address critical healthcare needs for patients with unmet medical requirements. PTC's strategic focus on leveraging scientific expertise and a robust global commercial infrastructure positions it to maximize value for both patients and stakeholders, reinforcing its reputation as a key player in the biopharmaceutical industry.

In addition to its workforce initiatives, PTC Therapeutics continues to engage with the broader community, providing updates on its progress and advancements through its website and social media channels. The company’s proactive communication strategy underscores its commitment to transparency and connection with stakeholders. For further inquiries, interested parties can contact Ellen Cavaleri for investor relations and Jeanine Clemente for media-related questions.